| 價格 | ¥13800 | ¥10600 | ¥17500 |
| 包裝 | 50mg | 25mg | 100mg |
| 最小起訂量 | 25mg |
| 發(fā)貨地 | 上海 |
| 更新日期 | 2026-05-08 |
| 中文名稱:化合物 (rel)-Oxaliplatin | 英文名稱:(rel)-Oxaliplatin |
| CAS:63121-00-6 | 品牌: TargetMol |
| 產(chǎn)地: 美國 | 保存條件: Keep away from direct sunlight,The compound is unstable in solution. Please use soon, Powder: -20°C for 3 years Shipping with blue ice/Shipping at ambient temperature. |
| 產(chǎn)品類別: 抑制劑 | |
| 貨號: T001|T61870 |
| 名稱 | (rel)-Oxaliplatin |
| 描述 | (rel)-Oxaliplatin is a DNA synthesis inhibitor that induces DNA crosslinking damage, inhibits DNA replication and transcription, and stimulates apoptosis. This compound has applications in cancer research [1] [2] [3]. |
| 體外活性 | (rel)-Oxaliplatin (24-72 hours; 2-128 μM; HCC, HCCLM3 and Hep3B cells) inhibits cell growth and induces apoptosis [1]. (rel)-Oxaliplatin (10 μM; 15-240 mins; CEM cells ) induces primary and secondary DNA lesions, including DNA cross-links (ISC) and DNA-protein cross-links (DPC) [2]. (rel)-Oxaliplatin (0.01 to 100 μM; 24 hours) potently inhibits bladder carcinoma cell lines RT4 and TCCSUP, ovarian carcinoma cell line A2780, colon carcinoma cell line HT-29, glioblastoma cell lines U-373MG and U-87MG, and melanoma cell lines SK-MEL-2 and HT-144 with IC 50 of 11 μM, 15 μM, 0.17 μM, 0.97 μM, 2.95 μM, 17.6 μM, 30.9 μM and 7.85 μM, respectively [3] Cell Viability Assay [1] Cell Line: HCC, HCCLM3 and Hep3B cells Concentration: 24, 48 and 72 hours Incubation Time: 2, 4, 8, 16, 32, 64 and 128 μM Result: Decreased cell viability in a dose- and time-dependent manner. Western Blot Analysis [1] Cell Line: HCCLM3 and Hep3B cells Concentration: 48 hours Incubation Time: 10 μM Result: Down-regulated the expression of Bcl-2 and Bcl-xL, and increased the expression of Bax. Cell Cycle Analysis [1] Cell Line: HCCLM3 and Hep3B cells Concentration: 24 hours Incubation Time: 10 μM Result: Increased the percentage of apoptotic cells (17.70% for HCCLM3 cells; 21.19% for Hep3B cells). |
| 體內(nèi)活性 | (rel)-Oxaliplatin (5-10 mg/kg; i.p.; for 32 days; nude mice) inhibits tumor growth [1]. Animal Model: Nude mice [1] Dosage: 5 and 10 mg/kg Administration: Intraperitoneal injection; for 32 days Result: Reduced tumor volume in HCCLM3 tumor xenografts. |
| 存儲條件 | Keep away from direct sunlight,The compound is unstable in solution. Please use soon, Powder: -20°C for 3 years Shipping with blue ice/Shipping at ambient temperature. |
| 溶解度 | DMSO : Slightly soluble, DMSO inactivates the activity of (rel)-Oxaliplatin. |
| 相關(guān)產(chǎn)品 | Formamide | Urea | Guanidine hydrochloride | Dimethyl phthalate | Aceglutamide | Alginic acid | Cysteamine hydrochloride | Metronidazole | Sildenafil citrate | Stavudine | Tamoxifen | Thymidine |
| 成立日期 | 2013-04-18 (14年) | 注冊資本 | 566.2651萬人民幣 |
| 員工人數(shù) | 100-500人 | 年營業(yè)額 | ¥ 1億以上 |
| 主營行業(yè) | 化學(xué)試劑,生物活性小分子 | 經(jīng)營模式 | 貿(mào)易,試劑,定制,服務(wù) |
| 產(chǎn)品名稱 | 價格 | 公司名稱 | 報價日期 | |
|---|---|---|---|---|
| 詢價 |
VIP4年
|
普善實業(yè)(陜西)有限公司
|
2026-06-26 | |
| 詢價 |
VIP5年
|
湖北魏氏化學(xué)試劑股份有限公司
|
2026-06-24 | |
| 詢價 |
VIP8年
|
麻城市進(jìn)鑫生物科技有限公司
|
2026-06-09 | |
| 詢價 |
VIP7年
|
陜西締都醫(yī)藥化工有限公司
|
2025-09-11 | |
| 詢價 |
河北茹麒科技有限公司
|
2023-06-27 | ||
| ¥300 |
湖北麥凱斯精化科技有限公司
|
2023-03-23 | ||
| 詢價 |
武漢楷倫化學(xué)新材料有限公司
|
2019-11-26 | ||
| 詢價 |
濟(jì)南大象國際貿(mào)易有限公司
|
2019-11-26 | ||
| 詢價 |
武漢楚豐源科技有限公司
|
2019-11-26 | ||
| 詢價 |
蘇州朗恩生物科技有限公司
|
2019-11-26 |